The Role of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema
No Thumbnail Available
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Pro Index
Abstract
Description
The article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug brolucizumab.
Keywords
diabetic macular edema, antiangiogenic therapy, ranibizumab